A Review on Positron Emission Tomography in Treatment of Alzheimer Disease

Abstract

Positron Emission Tomography (PET) is a noninvasive imaging technique and it allows the visualization of molecular processor and the early disease was detected and it is also used to measure the metabolic activity of the cells of the body tissues. It is a combination of nuclear medicine and combined biochemical elements. Alzheimer's disease (AD) is a neurodegenerative disorder, which causes memory loss and other functional disorders. Amyloid is an abnormal protein that is produced by your bone marrow and settled in any tissue or any organ. In this, we go to see, its advantage, disadvantage, and its applications for diagnosis of Alzheimer disease & amyloid fibrils in the human body. The study of PET proves the demonstration of the abnormalities maybe, cause in the prodromal stages of AD and cause damage, which carrying susceptibility genes. PET which radiotracers and neuropathological specifications are crucial to determine amyloid and to assess treatment response in clinical tests. The majority of these test examinations in AD patients have focused on AD imaging technic, and several ‘non-amyloid' substances are radiopharmaceuticals used for evaluating neurodegeneration, neuroinflammation, and excitations given by neurotransmission across the spectrum of AD, potentially examine to improve the therapeutic perspectives for Alzheimer disease (AD).